Healthcare provider profile · identity verified

Mark J. Tatara, MD

Internal Medicine · DOWNERS GROVE, IL · NPI 1043256324

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	736	217
Amlodipine Besylate	Amlodipine Besylate	414	127
Lisinopril	Lisinopril	339	92
Metformin Hcl	Metformin Hcl	300	85
Levothyroxine Sodium	Levothyroxine Sodium	295	79
Hydrochlorothiazide	Hydrochlorothiazide	278	85
Metoprolol Succinate	Metoprolol Succinate	269	77
Tamsulosin Hcl	Tamsulosin Hcl	235	76
Losartan Potassium	Losartan Potassium	221	69
Simvastatin	Simvastatin	195	52
Allopurinol	Allopurinol	154	45
Omeprazole	Omeprazole	154	47
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	132	36
Metoprolol Tartrate	Metoprolol Tartrate	129	35
Gabapentin	Gabapentin	125	36
Glipizide	Glipizide	121	36
Pantoprazole Sodium	Pantoprazole Sodium	121	31
Sertraline Hcl	Sertraline Hcl	115	30
Escitalopram Oxalate	Escitalopram Oxalate	111	23
Albuterol Sulfate Hfa	Albuterol Sulfate	109	46
Fluticasone Propionate	Fluticasone Propionate	108	33
Meloxicam	Meloxicam	105	35
Furosemide	Furosemide	100	30
Duloxetine Hcl	Duloxetine Hcl	83	17
Rosuvastatin Calcium	Rosuvastatin Calcium	81	29
Clopidogrel	Clopidogrel Bisulfate	80	24
Potassium Chloride	Potassium Chloride	71	25
Tramadol Hcl	Tramadol Hcl	71	18
Celecoxib	Celecoxib	67	21
Eliquis	Apixaban	67	11
Trazodone Hcl	Trazodone Hcl	65	19
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	62	15
Famotidine	Famotidine	58	19
Diclofenac Sodium	Diclofenac Sodium	57	14
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	56	15
Telmisartan	Telmisartan	52	14
Finasteride	Finasteride	51	13
Atenolol	Atenolol	50	11
Oxybutynin Chloride	Oxybutynin Chloride	50	15
Jardiance	Empagliflozin	49	14
Carvedilol	Carvedilol	48	17
Montelukast Sodium	Montelukast Sodium	47	19
Pravastatin Sodium	Pravastatin Sodium	47	13
Alprazolam	Alprazolam	44	11
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	42	13
Januvia	Sitagliptin Phosphate	42	11
Alendronate Sodium	Alendronate Sodium	40	14
Citalopram Hbr	Citalopram Hydrobromide	38	suppressed
Enalapril Maleate	Enalapril Maleate	35	suppressed
Prednisone	Prednisone	35	25
Azithromycin	Azithromycin	34	32
Zolpidem Tartrate	Zolpidem Tartrate	34	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	33	suppressed
Glipizide Er	Glipizide	33	suppressed
Lorazepam	Lorazepam	33	suppressed
Metformin Hcl Er	Metformin Hcl	33	13
Sumatriptan Succinate	Sumatriptan Succinate	33	suppressed
Bupropion Xl	Bupropion Hcl	32	suppressed
Glimepiride	Glimepiride	32	11
Synthroid	Levothyroxine Sodium	32	suppressed
Farxiga	Dapagliflozin Propanediol	30	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	30	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	30	suppressed
Lovastatin	Lovastatin	30	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	29	24
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	28	suppressed
Topiramate	Topiramate	28	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	26	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	26	suppressed
Symbicort	Budesonide/Formoterol Fumarate	26	suppressed
Benazepril Hcl	Benazepril Hcl	25	suppressed
Colchicine	Colchicine	25	suppressed
Ipratropium Bromide	Ipratropium Bromide	24	13
Ondansetron Odt	Ondansetron	24	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	24	suppressed
Spironolactone	Spironolactone	24	suppressed
Warfarin Sodium	Warfarin Sodium	24	suppressed
Breo Ellipta	Fluticasone/Vilanterol	23	suppressed
Hydralazine Hcl	Hydralazine Hcl	23	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	23	12
Paroxetine Hcl	Paroxetine Hcl	23	suppressed
Xarelto	Rivaroxaban	23	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	22	suppressed
Valsartan	Valsartan	21	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	20	20
Baclofen	Baclofen	20	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	20	suppressed
Diazepam	Diazepam	19	suppressed
Mirtazapine	Mirtazapine	19	suppressed
Nifedipine Er	Nifedipine	19	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	18	suppressed
Torsemide	Torsemide	18	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	17	suppressed
Haloperidol	Haloperidol	17	suppressed
Meclizine Hcl	Meclizine Hcl	17	suppressed
Memantine Hcl	Memantine Hcl	17	suppressed
Myrbetriq	Mirabegron	17	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	17	suppressed
Ramipril	Ramipril	17	suppressed
Sildenafil Citrate	Sildenafil Citrate	17	suppressed
Terazosin Hcl	Terazosin Hcl	17	suppressed
Dutasteride	Dutasteride	16	suppressed
Ezetimibe	Ezetimibe	16	suppressed
Ketorolac Tromethamine	Ketorolac Tromethamine	16	suppressed
Bumetanide	Bumetanide	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	15	suppressed
Levemir Flexpen	Insulin Detemir	15	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	15	suppressed
Ozempic	Semaglutide	15	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	14	suppressed
Irbesartan	Irbesartan	14	suppressed
Nabumetone	Nabumetone	14	suppressed
Oxycodone Hcl	Oxycodone Hcl	14	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	14	14
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	suppressed
Amantadine	Amantadine Hcl	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Fenofibrate	Fenofibrate	13	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Klor-Con M20	Potassium Chloride	13	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Primidone	Primidone	13	suppressed
Azelastine Hcl	Azelastine Hcl	12	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Galantamine Hbr	Galantamine Hbr	12	suppressed
Mometasone Furoate	Mometasone Furoate	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Trulicity	Dulaglutide	12	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Humalog Mix 75-25	Insulin Lispro Protamin/Lispro	11	suppressed
Novolog Flexpen	Insulin Aspart	11	suppressed
Pregabalin	Pregabalin	11	suppressed
Tresiba Flextouch U-100	Insulin Degludec	11	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error